心先安在重症充血性心力衰竭治疗中的应用

Treatment with heart Ann first for the severve congestive heart failure patients

目的:探讨心先安治疗重症充血性心力衰竭的临床疗效。方法:连续收集2012年10月至2014年2月于我院就诊的100例重症充血性心力衰竭患者的相关资料,按照入院顺序随机分为观察组和对照组,各50例。对照组接受常规治疗,观察组在常规治疗的基础上,将180mg心先安加入250ml 10%的葡萄糖注射液中进行静脉滴注,14d后对比两组治疗效果、心功能分级、左室射血分数、心排指数等。结果:观察组治疗总有效率高于对照组,再住院率低于对照组,差异具有统计学意义(P<0.05);治疗后,观察组患者心功能分级、血压、HR、左室射血分数(LVEF)、心排指数(CI)、左室短轴缩短率(FS)、心脏每搏量(SV)等均优于对照组,差异具有显著性(P<0.05);观察组6min步行距离较对照组明显延长(P<0.05)。结论:心先安可改善重症充血性心衰患者心功能,降低再住院率。

Objective： To explore the heart Ann first clinical curative effect for the treatment of severe congestive heart failure. Methods： Collection in October 2012 to February 2014 in our hospital during the period of 100 patients with severe congestive heart failure related information, according to admission order were randomly divided into observation group and control group, 50 cases each. Control group accepted routine treatment, the observation group based on this intention to 180 mg of Ann to join 10%hydatidiform mole injection intravenous drip in 250 ml, compared two groups of treatment effect after 14 d and grade of cardiac function and left ventricular ejection fraction and cardiac index, etc. Results： Treatment group total effectiveness is higher than the observed, then the hospitalization rate is lower than the control group, the difference is statistically significant （P〈0.05）; After treatment, the observation group of patients with cardiac function classification, blood pressure, HR, LVEF, CI, FS and SV were superior to control group, with significant difference （P〈0.05）; The observation group 6 min walking distance was significantly longer （P〈0.05）. Conclusions： The heart first encore improves cardiac function in patients with severe congestive heart failure, reduce hospitalization rates again.